GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

An observational study of 175 health outcomes using Veterans Affairs (VA) data for nearly 2 million individuals uncovered new insights about possible risks and benefits of GLP-1 receptor agonists.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

GLP-1RAs are antihyperglycemic agents with protective cardiovascular ... a total of 215,970 candidates who were enrolled between 1 October 2017 and 31 December 2023, consisting mostly of White ...

The researchers noted that patients on GLP-1s have an 11% and 146 ... them against a control group of about 1.7M who received other blood sugar-lowering agents. Al-Aly highlighted the need to ...